Navigation Links
Andromeda Biotech: A drug for type 1 diabetes
Date:11/22/2011

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way. In addition, all of the patients received insulin as needed to stabilize their glucose levels.

DiaPep277 was invented by Prof. Irun Cohen and his team at the Weizmann Institute of Science. This unique peptide, containing 24 amino acids, is derived from the sequence of the human heat shock protein 60 (Hsp60). The peptide acts by modulating the immune system, preventing the destruction of the pancreatic cells that secrete insulin and preserving their natural function. Treatment of Type 1 diabetes patients with DiaPep277 may have several medical benefits: slowing the deterioration of the diseased tissue, improved metabolic control, a reduction in daily insulin requirements and fewer complications of diabetes.

During the trial, the ability of the patients' pancreas to secrete insulin was tested. From an initial analysis of the results, it appears that the patients treated with the drug for a year or more had significantly higher pancreas function than those in the control group.

From the point of view of safety, no significant differences were found in the incidence of side effects between the treated and control groups.

Additional data on the drug's efficacy and safety were collected and evaluated, and these will be presented in a final report on the trial, which will be completed in several months.

Andromeda Biotech is now planning to conduct another trial, to try to reproduce these results. Recruitment of patients into this trial is expected to be finalized in the second quarter of 2012. The research and development team of Andromeda Biotech emphasize that the drug is still under development, and there is no absolute guarantee that the drug will eventually be marketed.


'/>"/>
Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Related biology news :

1. Vegetarian diet, physical activity protect against diabetes in black population, study shows
2. Animal study suggests that newborn period may be crucial time to prevent later diabetes
3. VTT identified specific bacteria which precede autoimmune diabetes
4. Joslin study finds clue to birth defects in babies of mothers with diabetes
5. Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity
6. Pitt team identifies key protein causing excess liver production of glucose in diabetes
7. Discovery of insulin switches in pancreas could lead to new diabetes drugs
8. Clues to finding further causes for monogenic diabetes
9. MU study links inactivity with risk factors for Type 2 diabetes
10. Joslin researchers identify new target for treatment of type 2 diabetes and prediabetes
11. How fatty diets cause diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):
(Date:9/14/2017)... London UK (PRWEB) , ... September 14, 2017 ... ... the most innovative minds in pharma and biotech at the third annual DrugDev ... collaborative conference that brings together the world’s most progressive clinical research leaders for ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ ... testing. In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent ...
(Date:9/14/2017)... (PRWEB) , ... September 14, 2017 , ... One of ... on Saturday, Sept. 16. , For six hours that day, the GenCure Marrow Donor ... at more than 30 H-E-B grocery stores in San Antonio. , The registration tables ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... and exploratory analytics solutions, today announced that its Anzo Smart Data Lake has ... KMWorld’s list includes technologies and solutions that help organizations succeed in surpassing their ...
Breaking Biology Technology: